{"id":"W2522519290","doi":"10.1016/j.ejca.2016.08.004","title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharma; Exelixis; Canadian Centre for Applied Research in Cancer Control; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Everolimus; Medicine; Oncology; Renal cell carcinoma; Internal medicine; Urology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002383427,0.001639415,0.00279216,0.0003837662,0.000337453,0.001500232,0.0009081244,0.001244582,0.005477799],"category_scores_gemma":[0.001705153,0.0006228156,0.003402878,0.0003374474,0.000848286,0.001623828,0.000358811,0.003796643,0.001127799],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009499635,"about_ca_system_score_gemma":0.001291711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007832279,"about_ca_topic_score_gemma":0.003296793,"domain_scores_codex":[0.9993761,0.0003261457,0.00002863604,0.0001023194,0.00005501049,0.0001117537],"domain_scores_gemma":[0.9991087,0.0002459885,0.0001554425,0.0001114315,0.00008066373,0.0002977495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8945634,0.008408101,0.003298781,0.001555081,0.007274096,0.0002063417,0.0001864145,0.002860846,0.008654138,0.0005083312,0.007588669,0.0648957],"study_design_scores_gemma":[0.8708114,0.1048918,0.0102664,0.0001138459,0.003717868,0.0003729966,0.0001095988,0.002157972,0.001238967,0.0006948276,0.005553167,0.00007115207],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743391,0.009169401,0.001602006,0.001922211,0.0004246711,0.00219082,0.005016261,0.000306453,0.005029077],"genre_scores_gemma":[0.974458,0.004491721,0.003546936,0.002333767,0.000334465,0.002134741,0.006874303,0.0001002024,0.005725876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005477799,"threshold_uncertainty_score":0.01832503,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05198801059173726,"score_gpt":0.3128697897938985,"score_spread":0.2608817792021612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}